U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06771180) titled 'Dara-BCD for Rare MGRS' on Jan. 08.

Brief Summary: This is an open-label, multicenter, phase 2 study in subjects with newly diagnosed proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMIDs), OR light chain proximal tubulopathy (LCPT), OR thrombotic Microangiopathy (TMA), OR cryoglobulinemic glomerulonephritis, (CGGN), treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.

Study Start Date: Jan. 15

Study Type: INTERVENTIONAL

Condition: Monoclonal Gammopathy of Renal Significance (MGRS)

Intervention: DRUG: Dara-CyBorD

Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR...